

# Preoperative chemoradiation with UFT-E plus leucovorin and translational study for locally advanced rectal cancer

<b>Submission date</b> 05/07/2016	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 25/07/2016	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/10/2017	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Rectal cancer is a type of cancer that develops in the large bowel. It's called rectal cancer because of its position within the length of the bowel. Patients that have been diagnosed with locally advanced rectal cancer (that is, cancer that has grown through the wall of the rectum but not yet spread to the lymph nodes) are often treated with both chemotherapy and radiation (chemoradiation) before they are considered for surgery. This study is investigating the success of a particular treatment; namely a high-dose of a drug called tegafur-uracil together with another one called leucovorin in addition to radiation therapy for patients before they undergo surgery for locally advanced rectal cancer.

### Who can participate?

Adults with locally advanced rectal cancer that have not yet been treated with chemotherapy.

### What does the study involve?

All participants are given radiotherapy plus chemotherapy treatment with tegafur-uracil (400mg/m<sup>2</sup>/day) and leucovorin (90mg/day). The drugs are given to each patient throughout their radiation treatment. All participants are then followed up to see whether their cancer has responded to the treatment, whether they suffered any ill effects from the treatment, how long it is before the cancer reoccurs. Overall survival rate data is also collected. Participants are also asked to give blood samples for pharmacogenetic analysis to see whether people with certain genetic profiles are more likely to be successfully treated than others.

### What are the possible benefits and risks of participating?

Participants are given the treatment without charge for the duration of the study. There could be some adverse effects from taking the high dose of tegafur-uracil.

### Where is the study run from?

National Cancer Center, Goyang (South Korea)

When is the study starting and how long is it expected to run for?  
October 2008 to November 2012

Who is funding the study?  
National Cancer Center, Goyang (South Korea)

Who is the main contact?  
Ms Hyun Mi Kim  
ncccolonco@hanmail.net

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Ms Hyun Mi Kim

**Contact details**  
323 Ilsan-ro, Ilsandong-gu  
Goyang  
Korea, South  
10408  
82-31-920-1145  
ncccolonco@hanmail.net

## Additional identifiers

**Protocol serial number**  
NCC-CTS-08-358

## Study information

**Scientific Title**  
A phase II study of preoperative chemoradiation with UFT-E plus leucovorin and the translational research for detection of predictive markers in the patients with locally advanced resectable rectal cancer

**Study objectives**  
Pathologic complete response rate with enteric coated tegafur-uracil(UFT-E) and leucovorin for locally advanced rectal cancer (cT3-4NxM0) would be more than 20%

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**  
Institutional Review Boards of National Cancer Center, Korea, 20/10/2008, ref: NCCCTS-08-358

**Study design**

Single-arm phase II study

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Locally advanced rectal cancer (cT3-4, Nx, M0)

## Interventions

This is a single-arm, phase II study of preoperative radiotherapy (RT) with enteric-coated tegafur-uracil (UFT-E) and leucovorin.

1. Radiotherapy (RT): started within 14 days after screening and obtaining informed consent. RT to whole pelvis at a dose of 45 Gy in 25 fractions, followed by 5.4 Gy in a three-fraction boost to the primary tumor.
2. Enteric-coated tegafur-uracil (UFT-E) : 400 mg/m<sup>2</sup> of tegafur divided into three daily doses without drug holidays during RT. - Since each package of UFT-E contains 500 mg of granules that corresponds to 100 mg of tegafur, the recommended dosing schedule according to body surface area (BSA) are as follows:
  - 2.1. BSA ≤ 1.37 m<sup>2</sup>: 2, 2, and 1 packages an hour after breakfast, lunch and dinner, respectively
  - 2.2. BSA 1.38 m<sup>2</sup> – 1.62 m<sup>2</sup>: 2, 2, and 2 packages; BSA 1.63 m<sup>2</sup> – 1.87 m<sup>2</sup>: 3, 2, and 2 packages
  - 2.3. BSA ≥ 1.88 m<sup>2</sup>: 3, 3, and 2 packages
3. Leucovorin: 30mg (2 tablets) p.o. With each UFT-E dose, corresponding to a total daily dose of 90 mg
4. Surgery: planned within 6 ± 2 weeks of the completion of RT. Total mesorectal excision is the first-choice surgical treatment

## Intervention Type

Drug

## Phase

Phase II

## Drug/device/biological/vaccine name(s)

1. Enteric-coated tegafur-uracil
2. Leucovorin

## Primary outcome(s)

Pathologic complete response by Dworak's classification, assessed with surgical specimen (including primary tumor and regional lymph nodes) derived from total mesorectal excision.

Dworak's classification:

Grade 0 no regression

Grade 1 dominant tumor mass with obvious fibrosis and/or vasculopathy Grade 2 dominantly fibrotic changes with few tumor cells or groups (easy to find)

Grade 3 very few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance

Grade 4 no tumor cells, only fibrotic mass (total regression or response)

## Key secondary outcome(s)

1. Safety: measured with National Cancer Institute Common Terminology Criteria (NCI-CTC) scale, version 3.0
2. Relapse-free survival : the time from the date of starting CRT to the date on which either of recurrence, progression, or death was first observed, or the date of last follow-up
3. Overall survival: the time from the date of starting CRT to the date of death from any cause or last follow-up
4. Pharmacogenetic analysis: genomic DNA from peripheral blood will be analyzed for the following polymorphism: CYP2A6\*4 (whole deletion of CYP2A6), CYP2A6\*7 (6558T>G, rs5031016), CYP2A6\*9 (-48T>G, rs28399433), CYP2A6\*10 (6558T>C and 6600G>T, rs28399468), UMPS 638G>C (rs1801019), ABCB1 3545 C>T (rs1045642), ABCB1 1236 C>T (rs1128503), and ABCB1 2677 G>T/A (rs2032582)

**Completion date**

30/11/2012

## Eligibility

**Key inclusion criteria**

1. Histologically diagnosed adenocarcinoma of rectum
2. Located within 8cm from anal verge
3. cT3/4 by rectal MRI+/- endorectal ultrasound
4. 18 years old or more
5. ECOG performance status <=2
6. No previous chemotherapy
7. No previous radiotherapy to pelvis
8. Adequate bone marrow, hepatic, and renal function

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Rectal cancer of histology other than adenocarcinoma
2. Adenocarcinoma developed from inflammatory bowel disease
3. Presence of distant metastases
4. Existence of unresected synchronous colon cancer
5. Unresolved bowel obstruction
6. Clinically unresectable disease
7. Uncontrolled cardiovascular disease

8. Uncontrolled active infection
9. History of other malignancies within 5 years from screening
10. History of organ transplantation that necessitates immunosuppressive treatment
11. Uncontrolled epileptic disease or psychiatric disease
12. Pregnant or breastfeeding women, or women with child-bearing potential who are not compliant to 13. Contraception policy of this study

**Date of first enrolment**

09/01/2009

**Date of final enrolment**

28/08/2012

## Locations

**Countries of recruitment**

Korea, South

**Study participating centre**

**National Cancer Center**

323 Ilsan-ro, Ilsandong-gu

Goyang

Korea, South

10408

## Sponsor information

**Organisation**

National Cancer Center

**ROR**

<https://ror.org/02tsanh21>

## Funder(s)

**Funder type**

Not defined

**Funder Name**

National Cancer Center

**Alternative Name(s)**

NCC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

Korea, South

## Results and Publications

### Individual participant data (IPD) sharing plan

**IPD sharing plan summary**

Available on request

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	27/03/2017		Yes	No